Advertisement

Topics

Imara Inc. Company Profile

19:33 EDT 20th March 2019 | BioPortfolio

Imara Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. The company was launched following an 18-month diligence and de-risking scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S with initial funding from life science investors NEA, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.


News Articles [16 Associated News Articles listed on BioPortfolio]

Imara raises $63m for sickle cell drug trials

US biotech Imara has raised $63 million for clinical development of its sickle cell disease drug, which is in mid-stage development. Imara attracted investors including Arix Bioscience, which has inv...

Imara closes $63m Series B cross-over financing

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates, The ...

Imara closes a $63m Series B cross-over financing

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates, The ...

Imara Broadens Hematology Horizons With $63m Fundraising

Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II...   

OrbiMed, Arix lead Imara's $63M B round

Imara raises $63mm through Series B crossover round

Imara Inc. raised $63mm through an oversubscribed Series B crossover round. New investors OrbiMed Advisors and Arix Bioscience co-led and were joined by additional first-time buyers RA Capital and Roc...

Blood disorder specialists Imara raises $63m

Arix Biosciences claims a 10% stake in the biotech

Imara Announces Presentation at the Annual Sickle Cell and Thalassaemia Conference

Company Provided Review of Ongoing Phase 2 Clinical Trial of IMR-687 Imara Inc. today announced it presented an update on its sickle cell disease program at the Annual Sickle ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

IMARA, Adapting SiHLE for Detained African American Adolescent Females

The IMARA Program will test the efficacy of a multi-session HIV Prevention program, adapted from an existing program(SiHLE), for incarcerated African American adolescent females.

An Integrated HIV Prevention Model for African American Mothers and Daughters

This study has three specific aims: 1. To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health program (FUELTM). The investigators will: ...

Companies [1 Associated Companies listed on BioPortfolio]

Imara Inc.

Imara Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease. Imara is developing IMR-687, a highly s...

More Information about "Imara Inc." on BioPortfolio

We have published hundreds of Imara Inc. news stories on BioPortfolio along with dozens of Imara Inc. Clinical Trials and PubMed Articles about Imara Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Imara Inc. Companies in our database. You can also find out about relevant Imara Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record